

**Guaranteed Investment Products 1 PCC Limited**

**Annual Financial Report and Audited Financial Statements**

**for the year ended 31 March 2019**

**Company Registration No: 42754**

**Guaranteed Investment Products 1 PCC Limited (the “Company”)  
CONTENTS**

	Page
Directors' Report	3
Shareholder Information	8
Independent Auditor's report	9
Audited Financial Statements	
Statement of Comprehensive Income	13
Statement of Financial Position	14
Statement of Changes in Net Assets Attributable to Holders of Protected Cell Guaranteed Shares	15
Statement of Cash Flows	16
Notes to the Financial Statements	17
Unaudited Schedule of Investments	38
Directors, Advisors and Other Information	39

**Guaranteed Investment Products 1 PCC Limited (the “Company”)  
DIRECTORS’ REPORT  
For the year ended 31 March 2019**

The directors are pleased to present their Annual Financial Report and Audited Financial Statements for the year ended 31 March 2019.

**INCORPORATION AND STRUCTURE**

Guaranteed Investment Products 1 PCC Limited (the “Company”) is a Guernsey-incorporated, closed-ended, protected cell company incorporated on 26 January 2005. The structure of the Company allows different cells to be created from time to time at the discretion of the directors for the purpose of segregating and protecting the assets of each cell, each with its own investment objective and policy and portfolio of assets. Persons investing in, or dealing with, a cell of the Company only have recourse, and their interests are limited, to the assets attributable to that cell from time to time, and they have no recourse to the assets of any other cell.

The Company has appointed Santander UK plc (“Santander”) as its investment advisor. This took effect from 17 January 2018, novating the previous agreement in place with Abbey National Treasury Services Limited (“ANTS”), a subsidiary of Santander. This took place due to certain UK regulatory developments requiring the largest UK banks to separate their core retail banking activities from their investment banking activities. As a result of this Santander had informed the Company that it would be prohibited from guaranteeing ANTS’s obligations from 1 January 2019. Therefore, in order to preserve the Company’s recourse to Santander in respect of the Plan Investments of any protected cells the preference shares in which had not matured before 1 January 2019, Santander novated such Plan Investments (and the corresponding Determination Agency Agreements) from ANTS to Santander. Throughout these financial statements, references to the “Investment Advisor” refer to the investment advisor in place as described above.

The Company’s non-cellular equity comprises two Management Shares of £1 each fully paid which are held by Anson Custody Limited and Anson Registrars Limited respectively under a declaration of trust in favour of JTC Fund Solutions (Guernsey) Limited, the Company’s secretary and administrator. Subject to The Companies (Guernsey) Law 2008 (as amended) (the “Law”), on a winding-up, the holders of Management Shares are entitled, after payment of all creditors of the Company and after a return of capital to the holders of Cell Shares and Nominal Shares, to be repaid an amount equal to the amount paid up on the Management Shares and all remaining assets in the Company which are not otherwise attributable to any Cell of the Company.

The Company currently has 23 cells (36 as at 31 March 2018) established in accordance with the “Law”. The Company currently has 500 million issued redeemable participating preference shares of 0.0001 pence each designated as a Protected Cell Guaranteed Share in a particular cell of the Company (the “Shares”). For regulatory purposes the Company is an authorised closed-ended fund in accordance with Section 8 of The Protection of Investors (Bailiwick of Guernsey) Law, 1987 as amended and The Authorised Closed-Ended Investment Schemes Rules 2008.

The Company has an unlimited life but the Shares issued in respect of each protected cell have a maturity date on which they are compulsorily redeemed. On the maturity date of the protected cell shares, shareholders receive the Investment Return per Share attributable to that protected cell. Details of the maturity date for the Shares issued in respect of each protected cell are set out in the securities note for that protected cell which can be found on the Company’s website at <http://www.jtcgroup.com/gipl>. Following the maturity of the Company’s final cell on 31 December 2020 it is envisaged that the Company will be wound-up.

The Company is a self managed, third country alternative investment fund (“AIF”) and as such has chosen to comply with the Alternative Investment Fund Managers Directive (“AIFMD”) by registering all cells launched after 1 July 2014 under the United Kingdom National Private Placement Regime and complying with all relevant reporting requirements in respect of this. By virtue of the relevant cells of the Company having no employees, and being self managed there are no remuneration disclosures to be made pursuant to Article 22 of the AIFMD. There have been no material changes to the information previously provided to investors required to be disclosed under Article 22 of the AIFMD.

**INVESTMENT OBJECTIVE AND POLICY**

The Company’s main objective is to achieve the investment return applicable to Shares issued in respect of each protected cell launched.

The assets of each protected cell are invested in accordance with the investment objectives and policies of that protected cell as set out in the individual cell’s securities note. The only source of funding available to the Company to acquire and/or enter into and/or support the plan investments designed to fund the amounts payable in respect of any protected cell Shares and/or any other amounts payable by the Company in connection with such Shares will derive from the capital contributed by the subscribers of such Shares.

## **Guaranteed Investment Products 1 PCC Limited (the “Company”) DIRECTORS’ REPORT - continued**

The Company and its Directors, in consultation with the Investment Advisor, are responsible for the formulation of the investment policy of each protected cell and any subsequent change to that policy.

It is the intention of the Directors that the investment objectives for each protected cell will be achieved by investing the net issue proceeds of the Shares issued in respect of a cell into an investment plan as set out in the relevant securities note. The investment plan of each cell consists of financial instruments provided, guaranteed and/or issued by Santander or any other person approved by the Company.

The returns on the investment plans are designed to enable the Company to meet its stated investment objective for each protected cell. The investment plans have been structured by the "Investment Advisor" to provide a cell, as at the relevant maturity date, with an amount equal to the aggregate investment return of the Shares issued in respect of that cell. The Company will invest an amount equal to the net issue proceeds of each protected cell in the relevant investment plan on admission to The International Stock Exchange ("TISE") of the relevant Shares.

On the maturity date of a particular cell, Shareholders of that cell will receive an amount equal to the investment return so long as the issuer of the investment plan satisfies its obligation to repay the investment return at the maturity date. If the issuer fails to meet its obligation and thus the Company is unable to meet its obligation to Shareholders, Anson Registrars Limited, as the Guarantee Claims Agent has the contractual obligation to require Santander Guarantee Company (the “Guarantor”) to serve notice on Santander to take all reasonable actions to ensure payment is made to the Shareholders of the protected cell. Any shortfall between the amount the Shareholders receive at the maturity date and the guaranteed return as set out in the relevant securities note is to be met by the Guarantor.

### **RESULTS & DISTRIBUTIONS**

The results of the Company for the Period are set out in an aggregated format on pages 13 - 16. Further information and commentary on the relevant investment performance of all cells is available from the following website <https://clear.santander.co.uk>

The directors did not declare a dividend for any cell during the year.

### **DIRECTORS**

The Company has three directors who are responsible for the implementation of the Company's investment policy and on-going management.

The current Directors of the Company are:

**Gavin Farrell** – Mr Farrell qualified as a Solicitor of the Supreme Court of England and Wales, a French Avocat and an Advocate of the Royal Court of Guernsey. He is a partner of Ferbrache & Farrell, Advocates & Notaries Public, in Guernsey and specialises in international and structured finance and collective investment schemes. He holds a number of directorships in investment and captive insurance companies. He is resident in Guernsey.

**John Le Prevost** - Mr Le Prevost is the Chief Executive Officer of Anson Group Limited and Chairman of Anson Registrars Limited (the Company's Registrar). He has spent over forty years working in offshore fund, trust and investment businesses during which time he has been a managing director of subsidiaries in Guernsey for County NatWest Investment Management, The Royal Bank of Canada and for Republic National Bank of New York. He is a Full Member of the Society of Trust and Estate Practitioners and in 1991-2 read for a law degree via distance learning and in 2009-11 read for an MBA from Southampton University via the Guernsey Training Agency. He is a non-executive director of a number of London listed investment companies and is a trustee of the Guernsey Sailing Trust. He is resident in Guernsey.

**Paul Meader** – Mr Meader is an independent director of a number of investment management companies, insurers and investment funds. Until 2013, he was Head of Portfolio Management for Canaccord Genuity based in Guernsey, having previously held the role of Chief Executive of Corazon Capital Group which was acquired by Collins Stewart in 2010. Prior to joining Corazon he was Managing Director of Rothschild's Swiss private-banking subsidiary in Guernsey. Mr Meader has 30 years' experience in financial markets with particular expertise in fixed income investments. He is a Chartered Fellow of the Chartered Institute of Securities & Investment and is past Chairman of the Guernsey International Business Association. He is resident in Guernsey.

## **Guaranteed Investment Products 1 PCC Limited (the “Company”) DIRECTORS’ REPORT - continued**

### **ADMINISTRATOR & SECRETARY**

JTC Fund Solutions (Guernsey) Limited (the “Secretary”) is a subsidiary of JTC plc. a company admitted to trading on the Main Market of the London Stock Exchange, and provides administration and secretarial services to the Company pursuant to the Administration and Secretarial Agreement dated 28 January 2005.

In such capacity, the Secretary is responsible for the general secretarial duties required by Section 171 of the Law and for ensuring that the Company complies with its continuing obligations as a company listed on TISE. The Secretary is also responsible for the Company’s general administrative functions including the calculation of the net asset value of protected cell Shares and the maintenance of the Company’s accounting records.

### **SUBSTANTIAL INTERESTS**

On 28 December 2018 Abbey National Nominees Limited resigned as market maker and Banco Santander S.A. was appointed as the new market maker.

The Company has been advised that for all protected cells Abbey National Nominees Limited held 100% of the Company’s issued Shares in each cell. As at **13 June 2019**, the Investment Advisor held approximately **[5]** per cent. of the net assets of the Company beneficially. The remainder of the Company’s assets were held non-beneficially. There have been no changes in those holdings as at the date of this report.

### **STATEMENT OF DIRECTORS’ RESPONSIBILITIES**

The directors are responsible for preparing the financial statements in accordance with applicable Guernsey Law and generally accepted accounting principles.

Guernsey company law requires the directors to prepare financial statements for each financial period which give a true and fair view of the state of affairs of the Company and of the profit or loss for that period.

In preparing those financial statements, the directors are required to:

- select suitable accounting policies and then apply them consistently;
- make judgments and estimates that are reasonable and prudent;
- state whether applicable accounting standards have been followed, subject to any material departures disclosed and explained in the financial statements; and
- prepare the financial statements on a going concern basis unless it is inappropriate to presume that the Company will continue in business.

The directors are responsible for keeping proper accounting records which disclose with reasonable accuracy at any time the financial position of the Company and to enable them to ensure that the accounts comply with the Law. They are also responsible for safeguarding the assets of the Company and for taking reasonable steps for the prevention and detection of fraud and other irregularities.

### **CORPORATE GOVERNANCE**

As the Company is an authorised collective investment scheme under the Authorised Closed-Ended Investment Schemes Rules 2008 it must report under the Finance Sector Code of Corporate Governance (the “Code”). At the Board meeting held 22 February 2012, the Board resolved to adopt the Board Governance Review document provided by the Secretary and evaluates its contents on an on-going basis. This document sets out the underlying principles of the Code, areas of compliance and provides explanations where the Company deviates from the provisions of the Code. This enables the Directors of the Company to document their governance practices and as such, the Board believes that the Board Governance Review document is suitable for an investment company of its kind.

The Board meets at least four times a year to consider the affairs of the Company in a prescribed and structured manner. The Board also has regular contact with the Secretary throughout the year. The Directors are kept fully informed of investment and financial controls and any other matters that are relevant to the business of the Company are brought to the attention of the Directors. The Directors also have access, where necessary in the furtherance of their duties, to professional advice at the expense of the Company.

## **Guaranteed Investment Products 1 PCC Limited (the “Company”) DIRECTORS’ REPORT - continued**

The Board has a breadth of experience relevant to the Company, and the Directors believe that any changes to the Board’s composition can be managed without undue disruption. When new directors are appointed to the Board, the necessary and appropriate induction is provided by the Board with input from the Administrator and Investment Advisor.

The Company has complied with the main principles of the Code, except those set out below:

- Principle 1.5 (Delegation to Management) is not applicable to the Company as there is no internal executive management of the Company. It was noted that matters were delegated to various service providers and powers and duties in respect thereof were specified within the relevant contractual arrangements.
- Principle 4.2 (Group Policies) is not applicable as while the Company’s accounts are consolidated into Santander UK plc’s accounts, the Board of the Company has the authority to determine its own policies and procedures.
- Principle 8 (Shareholder Relations) is not applicable to the Company due to its distinct structure whereby Banco Santander S.A. is the sole Shareholder of the Company’s cells.

For the reasons set out in the preamble to the Code, the Board considers that these provisions are not relevant to the Company, and so the Company has therefore not reported further.

As per the Company’s Articles of Incorporation the Directors are not subject to re-election by the Shareholders nor are they appointed for specific terms as required by these provisions as this is not felt to be appropriate for the structure and nature of the Company. However, the Board has determined that in order to facilitate good corporate governance practice each of the Directors will offer themselves for re-election every three years.

The Directors place a high degree of importance on ensuring that high standards of corporate governance are maintained within the Company.

### **AUDIT COMMITTEE**

An Audit Committee has been established consisting of Mr Farrell, Mr Le Prevost (Chairman) and Mr Meader. The Audit Committee examines the effectiveness of the Company’s internal control systems, the annual and interim reports and financial statements, the auditors’ remuneration and engagement, as well as the Auditors’ independence and any non-audit services provided by them. The Audit Committee receives information from the Secretary’s compliance department and the external auditors.

### **INTERNAL CONTROLS**

The Board is responsible for the Company’s system of internal control and for reviewing its effectiveness. The Board confirms that there is an on-going process for identifying, evaluating and managing the significant risks faced by the Company. This process has been in place for the period under review and up to the date of approval of this Annual Financial Report. The process is reviewed by the Board on a regular basis.

The Board has reviewed the effectiveness of the system of internal control. In particular, it has reviewed and updated the process for identifying and evaluating the significant risks affecting the Company and the policies by which these risks are managed.

The internal control systems are designed to meet the Company’s particular needs and the risks to which it is exposed. Accordingly, the internal control systems are designed to manage rather than eliminate the risk of failure to achieve business objectives and by their nature can only provide reasonable and not absolute assurance against misstatement and loss.

**Guaranteed Investment Products 1 PCC Limited (the “Company”)  
DIRECTORS’ REPORT - continued**

**AUDITORS**

Further to a tender process conducted in December 2015, the Board of Directors of the Company identified Ernst & Young LLP as the most appropriate auditor to the Company. Ernst & Young LLP have expressed their willingness to continue in office as Auditors and a resolution for their re-appointment will be put to the management shareholders at the forthcoming General Meeting of the Company to be held pursuant to Section 199 of the Law.

So far as each of the Company’s Directors is aware there is no relevant information of which the Company’s auditor is unaware and each has taken all of the steps he ought to have taken as a director to make himself aware of any relevant audit information and to establish that the Company’s auditor is aware of that information.

**GOING CONCERN**

The Company’s financial position, cash flows and liquidity position are set out in the financial statements and the Company’s financial risk management objectives and policies are set out at the notes to the financial statements on pages 13 - 37.

As disclosed in the notes to the financial statements, the only financial commitments of the Company are its on-going operating expenses and obligations to the Shareholders on the redemption of their cell Shares. Save for its own fee and the Marketing Agent’s fee, the Investment Advisor has agreed to meet all other costs and expenses relating to the operation of the Company, any cells currently established or created in the future, the cost of listing any Shares on the TISE, the costs associated with the termination of each cell and the liquidation of the Company, including the initial launch costs and on-going costs.

The Company has access in the event of an insolvency event on the part of the Investment Advisor or in the event that the Investment Advisor has refused to meet a cost or expense incurred, to a £125,000 reserve to meet the costs associated with the operation of the Company. On 7 March 2019 the Company paid an amount of £5,388 for Directors and Officers Insurance which resulted in the emergency fund balance decreasing. The Investment Advisor paid the outstanding amount to the Company on 14 May 2019 in order for it to maintain the reserve amount of £125,000.

Upon the redemption of the Shares of a cell, the holders of such Shares shall only be entitled to the Investment Plan Return of such Shares. This is calculated by reference to the proceeds received under the relevant contract entered into between the Company acting on behalf of the relevant cell and the issuer of the investment plan on the maturity or termination of the contract.

The Company has seen a number of its cells, each of which had a fixed life, redeem during the year. The Directors do not consider that these redemptions have had a material impact on the going concern basis of the Company.

Given the nature of the Company and its investments, the Directors are satisfied that it will be appropriate to continue to adopt the going concern basis in preparing the financial statements for the next twelve months. The final cell will mature on 17 December 2020 and the Directors are satisfied that it will not be appropriate to continue to adopt the going concern basis in preparing the financial statements for the following year.

On behalf of the Board

John Le Prevost  
Director  
25 June 2019

**Guaranteed Investment Products 1 PCC Limited (the “Company”)  
SHAREHOLDER INFORMATION**

The Company announces the net asset value per protected cell Share on TISE on a monthly basis.

The Company's register of shareholders is maintained by Anson Registrars Limited in Guernsey and they can be contacted on +44 (0) 1481 711301.

The Directors are always available to enter into dialogue with investors and are willing to meet the major investors in the Company, as the Company believes such communication to be important. The Company's Directors can be contacted at the Company's registered office.

**Guaranteed Investment Products 1 PCC Limited (the “Company”)**  
**INDEPENDENT AUDITOR’S REPORT TO THE MEMBERS OF GUARANTEED INVESTMENT PRODUCTS 1 PCC LIMITED**

**Opinion**

We have audited the financial statements of Guaranteed Investment Products 1 PCC Limited (the ‘Company’) for the year ended 31 March 2019 which comprise the Statement of Comprehensive Income, the Statement of Financial Position, the Statement of Changes in Net Assets Attributable to Holders of Protected Cell Guaranteed Shares, the Statement of Cash Flows and the related notes 1 to 11, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and International Financial Reporting Standards.

In our opinion, the financial statements:

- give a true and fair view of the state of the Company’s affairs as at 31 March 2019 and of its profit for the year then ended;
- have been properly prepared in accordance with International Financial Reporting Standards; and
- have been properly prepared in accordance with the requirements of the Companies (Guernsey) Law, 2008.

**Basis for Opinion**

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditor’s responsibilities for the audit of the financial statements section of our report below. We are independent of the Company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC’s Ethical Standard as applied to listed entities, and we have fulfilled our other ethical responsibilities in accordance with these requirements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

**Conclusions relating to going concern**

We have nothing to report in respect of the following matters, in relation to which the ISAs (UK) require us to report to you where:

- the directors’ use of the going concern basis of accounting in the preparation of the financial statements is not appropriate; or
- the directors have not disclosed in the financial statements any identified material uncertainties that may cast significant doubt about the Company’s ability to continue to adopt the going concern basis of accounting for a period of at least twelve months from the date when the financial statements are authorised for issue.

**Overview of our audit approach**

---

Key audit matters	▶ Valuation of derivative financial instruments
Materiality	▶ Overall materiality of £12.3m which represents 2% of the Company’s net asset value (“NAV”) as at 31 March 2019

---

**Key audit matters**

Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the financial statements of the current period and include the most significant assessed risks of material misstatement (whether or not due to fraud) that we identified. These matters included those which had the greatest effect on: the overall audit strategy, the allocation of resources in the audit; and directing the efforts of the engagement team. These matters were addressed in the context of our audit of the financial statements as a whole, and in our opinion thereon, and we do not provide a separate opinion on these matters.

**Guaranteed Investment Products 1 PCC Limited (the “Company”)**

**INDEPENDENT AUDITOR’S REPORT TO THE MEMBERS OF GUARANTEED INVESTMENT PRODUCTS 1 PCC LIMITED - continued**

Risk	Our response to the risk	Key observations communicated to the Audit Committee
<p><b>Valuation of derivative financial instruments (2019: £613.4; 2018: £749.3m)</b></p> <p>The fair value of the Company’s investments in derivative financial instruments are not directly market-observable and are therefore based on valuation models that utilise inputs that are observable in active markets. Such valuation can require significant judgement and estimation as explained in note 2 to the financial statements.</p> <p>The fair value of the derivatives may be misstated due to application of inappropriate methodologies or inputs to the valuations and/or inappropriate judgmental factors or management override.</p> <p>As the Company’s derivative investments comprise 100% (2018: 100%) of the Company’s net asset value, any misstatement in their valuation could have a significant impact on the Company’s reported financial position and performance for the year.</p>	<p>We confirmed our understanding of the processes, policies and methodologies used to value the Company’s derivatives, and the processes used by the Board to review these valuations. We assessed whether such valuations had been performed in accordance with IFRS and the Company’s accounting policies. We performed detailed analytical review procedures on the valuations, including comparisons to indexes and comparisons to the minimum and maximum returns, to ensure the reasonableness of the valuations.</p> <p>We have performed procedures to review the investment performance in relation to the benchmarks to which the returns on the derivatives are contractually linked.</p> <p>We engaged our own internal valuation specialists to independently value a sample of the derivative valuations using market data from independent sources.</p>	<p>We confirmed that there were no material instances of use of inappropriate policies or methodologies that we wanted to bring to the attention of the Audit Committee, and that the valuation of the underlying investments was not materially misstated.</p>

**An overview of the scope of our audit**

**Tailoring the scope**

Our assessment of audit risk, our evaluation of materiality and our allocation of performance materiality determine our audit scope. Taken together, this enables us to form an opinion on the financial statements. We take into account size, risk profile, the organisation of the company and the effectiveness of controls, including controls and changes in the business environment when assessing the level of work to be performed.

**Our application of materiality**

We apply the concept of materiality in planning and performing the audit, in evaluating the effect of identified misstatements on the audit and in forming our audit opinion.

**Materiality**

*Materiality is the magnitude of an omission or misstatement that, individually or in the aggregate, could reasonably be expected to influence the economic decisions of the users of the financial statements. Materiality provides a basis for determining the nature and extent of our audit procedures.*

We determined materiality for the Company to be £12.3m (2018: £15m), which is 2% (2018: 2%) of the Company’s net asset value. We believe that this provided an appropriate basis for determining planning materiality because the Company’s primary performance measures for internal and external reporting are based on net asset value.

Since our initial assessment of materiality, which was conducted at the planning stage of our audit, the net asset value of the Company has decreased. We have adjusted our materiality levels accordingly.

## **Guaranteed Investment Products 1 PCC Limited (the “Company”)**

### **INDEPENDENT AUDITOR’S REPORT TO THE MEMBERS OF GUARANTEED INVESTMENT PRODUCTS 1 PCC LIMITED - continued**

#### **Performance materiality**

*Performance materiality is the application of materiality at the individual account or balance level. It is set at an amount to reduce to an appropriately low level the probability that the aggregate of uncorrected and undetected misstatements exceeds materiality.*

On the basis of our risk assessments, together with our assessment of the Company’s overall control environment, our judgement was that performance materiality was 75% (2018: 75%) of our planning materiality, namely £9.2m (2018: £11.25m). We have set performance materiality at this level because we consider the likelihood of misstatements to be low. We have considered both quantitative and qualitative factors when determining the expected level of detected misstatements and setting the performance materiality at this level.

#### **Reporting threshold**

*Reporting threshold is an amount below which identified misstatements are considered as being clearly trivial.*

We agreed with the Audit Committee that we would report to them all uncorrected audit differences in excess of £613,000 (2018: £750,000), which is set at 5% of planning materiality, as well as differences below that threshold that, in our view, warranted reporting on qualitative grounds.

We evaluate any uncorrected misstatements against both the quantitative measures of materiality discussed above and in light of other relevant qualitative considerations in forming our opinion.

#### **Other information**

The other information comprises the information included in the annual report, other than the financial statements and our auditor’s report thereon. The Directors are responsible for the other information.

Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in this report, we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements, or our knowledge obtained in the audit, or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether there is a material misstatement in the financial statements or a material misstatement of the other information. If, based on the work we have performed, we conclude that there is a material misstatement of the other information, we are required to report that fact.

We have nothing to report in this regard.

#### **Matters on which we are required to report by exception**

We have nothing to report in respect of the following matters in relation to which the Companies (Guernsey) Law, 2008 requires us to report to you if, in our opinion:

- proper accounting records have not been kept by the Company; or
- the financial statements are not in agreement with the Company’s accounting records and returns; or
- we have not received all the information and explanations we require for our audit

**Guaranteed Investment Products 1 PCC Limited (the “Company”)**  
**INDEPENDENT AUDITOR’S REPORT TO THE MEMBERS OF GUARANTEED INVESTMENT PRODUCTS 1 PCC LIMITED - continued**

**Responsibilities of directors**

As explained more fully in the Statement of Directors’ Responsibilities set out on page 5, the directors are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the Directors determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the Directors are responsible for assessing the Company’s ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Directors either intend to liquidate the Company or to cease operations, or have no realistic alternative but to do so.

**Auditor’s responsibilities for the audit of the financial statements**

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor’s report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

A further description of our responsibilities for the audit of the financial statements is located on the Financial Reporting Council’s website at <https://www.frc.org.uk/auditorsresponsibilities>. This description forms part of our auditor’s report.

**Use of our report**

This report is made solely to the Company’s members, as a body, in accordance with Section 262 of the Companies (Guernsey) Law, 2008. Our audit work has been undertaken so that we might state to the Company’s members those matters we are required to state to them in an auditor’s report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the Company and the Company’s members as a body, for our audit work, for this report, or for the opinions we have formed.

**Ernst & Young LLP**

**25 June 2019**  
Guernsey  
Channel Islands

Notes:

1. The maintenance and integrity of the Guaranteed Investment Products 1 PCC Limited website is the responsibility of the Directors; the work carried out by the auditors does not involve consideration of these matters and, accordingly, the auditors accept no responsibility for any changes that may have occurred to the financial statements since they were initially presented on the web site.
2. Legislation in Guernsey governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions.

**Guaranteed Investment Products 1 PCC Limited**  
**STATEMENT OF COMPREHENSIVE INCOME**  
**For the year ended 31 March 2019**

	Notes	Year ended 31 March 2019 Total GBP	Year ended 31 March 2018 Total GBP
Unrealised gain on investments	4	28,837,067	11,764,171
Unrealised loss on investments	4	(31,315,160)	(13,916,260)
Realised gains on investments	4	<u>34,817,593</u>	<u>12,510,803</u>
Net gain on investments		32,339,500	10,358,714
Profit for the year attributable to holders of shares		<u><u>32,339,500</u></u>	<u><u>10,358,714</u></u>

The profit for the year attributable to holders of shares is also the total comprehensive income for the year.

The notes on pages 17 to 37 form an integral part of these financial statements

**Guaranteed Investment Products 1 PCC Limited**  
**STATEMENT OF FINANCIAL POSITION**  
**as at 31 March 2019**

	Notes	As at 31 March 2019 Total GBP	As at 31 March 2018 Total GBP
<b>NON CURRENT ASSETS</b>			
Investments	4	538,868,192	584,554,300
<b>CURRENT ASSETS</b>			
Investments	4	74,523,176	164,795,516
Receivables	5	5,388	-
Cash and cash equivalents		119,614	125,002
		<u>74,648,178</u>	<u>164,920,518</u>
<b>CURRENT LIABILITIES</b>			
Emergency fund from Santander		(125,000)	(125,000)
		<u>(125,000)</u>	<u>(125,000)</u>
		<u>613,391,370</u>	<u>749,349,818</u>
<b>NET ASSETS ATTRIBUTABLE TO HOLDERS OF PROTECTED CELL GUARANTEED SHARES</b>			
Non Current	3	538,868,192	584,554,300
Current	3	74,523,176	164,795,516
		<u>613,391,368</u>	<u>749,349,816</u>
<b>EQUITY</b>			
Management Shares	3	2	2
		<u>2</u>	<u>2</u>
		<u>613,391,370</u>	<u>749,349,818</u>

The financial statements on pages 13 to 35 were approved and authorised for issue by the Board of directors on 25 June 2019 and were signed on its behalf by:

John Le Prevost  
 Director

The notes on pages 17 to 37 form an integral part of these financial statements

**Guaranteed Investment Products 1 PCC Limited**  
**STATEMENT OF CHANGES IN NET ASSETS ATTRIBUTABLE TO HOLDERS OF PROTECTED CELL**  
**GUARANTEED SHARES**  
**For the year ended 31 March 2019**

	<b>Notes</b>	<b>Year ended 31 March 2019 Total GBP</b>	<b>Year ended 31 March 2018 Total GBP</b>
Opening balance		749,349,816	827,674,346
Reduction in capital on redemption of Shares	6	(138)	(78)
Reduction in premium on redemption of Shares	7	(136,216,844)	(78,214,264)
Reduction in other reserves on redemption of Shares	7	(32,080,966)	(10,468,902)
Profit for the year attributable to holders of Shares		32,339,500	10,358,714
Balance at year end		<u>613,391,368</u>	<u>749,349,816</u>

IAS 7 Statement of Cash Flows now requires a reconciliation of changes in financing liabilities split between cash and non-cash elements. Given the only significant liabilities of the Company are its shares, this information is already presented in the Statement of Net Assets Attributable to Holders of Protected Cell Guaranteed Shares.

The notes on pages 17 to 37 form an integral part of these financial statements

**Guaranteed Investment Products 1 PCC Limited**  
**STATEMENT OF CASH FLOWS**  
**For the year ended 31 March 2019**

	Year ended 31 March 2019	Year ended 31 March 2018
	Total GBP	Total GBP
<b>Operating activities</b>		
Profit for the year attributable to holders of shares	32,339,500	10,358,714
Realised gains on investments	(34,817,593)	(12,510,803)
Unrealised gains on investments	(28,837,067)	(11,764,171)
Unrealised losses on investments	31,315,160	13,916,260
Movement in receivables and payables during the period	(5,388)	(18,530)
Net cash flow used in operating activities	<u>(5,388)</u>	<u>(18,530)</u>
<b>Investing activities</b>		
Proceeds of maturity of financial assets	168,297,948	88,701,318
Net cash flow from investing activities	<u>168,297,948</u>	<u>88,701,318</u>
<b>Financing activities</b>		
Redemption of Shares	(168,297,948)	(88,683,244)
Net cash flow used in financing activities	<u>(168,297,948)</u>	<u>(88,683,244)</u>
Decrease in cash and cash equivalents	<u>(5,388)</u>	<u>(456)</u>
Cash and cash equivalents at beginning of year	125,002	125,458
Decrease in cash and cash equivalents	(5,388)	(456)
Cash and cash equivalents at end of year	<u>119,614</u>	<u>125,002</u>

The notes on pages 17 to 37 form an integral part of these financial statements

**Guaranteed Investment Products 1 PCC Limited**  
**Notes to the Financial Statements**  
**For the year ended 31 March 2019**

**1 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES**

**(a) Basis of preparation**

The financial statements have been prepared in conformity with International Financial Reporting Standards ("IFRS") and applicable Guernsey law. The financial statements give a true and fair view, comply with the Companies (Guernsey) Law, 2008 and have been prepared on a historical cost basis except for the measurement at fair value of financial instruments.

The financial statements are expressed in pounds Sterling, which is the functional and presentation currency of the Company.

**(b) Investment Advisor's Fees**

Investment Advisor's fees are paid at the inception of the cell to which they relate, and are charged to the Statement of Comprehensive Income on the date paid.

**(c) Taxation**

The Company has been granted exemption from Guernsey Income Tax under the Income Tax (Exempt Bodies) (Guernsey) (Amendment) Ordinance, 2012. The annual tax exempt fee is £1,200.

**(d) Investments**

All investments were previously classified as "fair value through profit and loss". On adoption of IFRS 9 these investments are mandatorily classified as "fair value through profit and loss", because the financial instrument contains one or more embedded derivatives, which significantly modify the cash flows that would otherwise be required by the contract. Investments are initially recognised at cost, being the fair value of the consideration given, excluding transaction costs associated with the investment. After initial recognition, investments are measured at fair value, with unrealised gains and losses on investments recognised in the Statement of Comprehensive Income. As detailed in note 2, the fair value of the investments is calculated based on valuations provided by the Issuer at the close of business on the reporting date. Investments are derecognised when the rights to cash flows from the investments have expired or substantially all risks and rewards of ownership have been transferred. Upon derecognition any previously recognised unrealised gain or loss is reversed in the current period's "unrealised gain on investments" and recognised in the "realised gain" along with any additional gain or loss recognised in the period. The "net gain on investments" shows the total gain or loss recognised in the current year.

**(e) Cash and Cash Equivalents**

At the reporting date cash and cash equivalents comprised cash at bank.

**(f) Shares**

As the Company's Shares mature on fixed dates and have non-identical features, they are classified in the financial statements as debt in accordance with IAS 32 Financial Instruments: Presentation. Whilst classified as liabilities, each Cell issues share capital and share premium in accordance with Guernsey Company Law. At the maturity date of a Cell, the liability due to Cell holders is de-recognised from the Statement of Financial Position, through a reduction in the net assets attributable to holders of shares, which represents a combination of initial proceeds and any further amounts included in the reserves since the date of issue. Management shares are classified as equity in the financial statements in accordance with IAS 32.

**(g) Net Asset Value**

The Net Asset Value per Share calculated in accordance with IFRS is based on net assets of the relevant protected cell as at 31 March 2019, as detailed in Note 3 to the Financial Statements.

The accounting policy for investments and the changes in the accounting policy for IFRS 9 'Financial Instruments' is therefore applicable.

**(h) Share premium**

The Company records proceeds from issues of shares in excess of their nominal value in share premium account. When Shares are redeemed, the redemption amount net of nominal value is debited to share premium account. The Cells are offered over a period of time before launch and proceeds collected from investors throughout that period.

**Guaranteed Investment Products 1 PCC Limited**  
**Notes to the Financial Statements**  
**For the year ended 31 March 2019**

**1 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES**

**(i) New and revised standard and interpretations**

New standards, amendments and interpretations effective for the periods beginning on or after 1 January 2018 and adopted by the Company.

- IFRS 9, 'Financial Instruments - Classification and Measurement'.

New interpretations is effective for annual periods beginning on or after 1 January 2019.

- IFRIC 23 'Uncertainty over Income Tax Treatments'

Management is assessing the impact of the above interpretation but are currently of the view that its impact is likely to be low.

There are no further standards, amendments or interpretations in issue at the reporting date which have been issued but are not yet effective and that are deemed to be material to the Company.

**(j) Changes in accounting policies**

***IFRS 9 'Financial Instruments'***

In accordance with IFRS 9, the Company classifies its financial assets and financial liabilities at initial recognition into the categories of amortised cost or fair value through profit or loss.

***Financial assets***

The Company classifies its financial assets at amortised cost or fair value through profit or loss on the basis of both:

- the entity's business model for managing the financial assets
- the contractual cash flow characteristics of the financial asset

***Financial assets measured at amortised cost***

A debt instrument is measured at amortised cost if it is held within a business model whose objective is to hold financial assets in order to collect contractual cash flows and its contractual terms give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding. The Company includes in this category short-term non-financing receivables including cash and trade and other receivables.

***Financial asset measured at fair value through profit or loss (FVPL)***

A financial asset is measured at fair value through profit or loss if:

- a) its contractual terms do not give rise to cash flows on specified dates that are solely payments of principal and interest (SPPI) on the principal amount outstanding; or
- b) it is not held within a business model whose objective is either to collect contractual cash flows, or to both collect contractual cash flows and sell; or
- c) it is classified as held for trading (derivative contracts in an asset position).

The Company includes in this category equity instruments and investments. There are no consolidated subsidiaries.

***Financial liabilities***

***Financial liabilities measured at fair value through profit or loss (FVPL)***

A financial liability is measured at FVPL if it meets the definition of held for trading of which the Company had none. The Company includes in this category, derivative contracts in a liability position.

**Guaranteed Investment Products 1 PCC Limited**  
**Notes to the Financial Statements**  
**For the year ended 31 March 2019**

**1 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES**

*Financial liabilities measured at amortised cost*

This category includes all financial liabilities, other than those measured at fair value through profit or loss, including short-term payables.

***Recognition and derecognition***

Financial assets and liabilities are recognised on trade date, when the company becomes party to the contractual provisions of the instrument. A financial asset is derecognised where the rights to receive cash flows from the asset have expired, or the Company has transferred its rights to receive cash flows from the asset. The Company derecognises a financial liability when the obligation under the liability is discharged, cancelled or expired.

***Impairment of financial assets***

The Company holds trade receivables with no financing component and which have maturities of less than 12 months at amortised cost and, as such, has chosen to apply an approach similar to the simplified approach for expected credit losses (ECL) under IFRS 9 to all its trade receivables. Therefore the Company does not track changes in credit risk, but instead recognises a loss allowance based on lifetime ECLs at each reporting date.

The Company's approach to ECLs reflects a probability-weighted outcome, the time value money and reasonable and supportable information that is available without undue cost or effort at the reporting date about past events, current conditions and forecasts of future economic conditions.

The Company uses the provision matrix as a practical expedient to measuring ECLs on trade receivables, based on days past due for groupings of receivables with similar loss patterns. Receivables are grouped based on their nature. The provision matrix based on historical observed loss rates over the expected life of the receivables and is adjusted for forward looking estimates.

***Retrospective application of IFRS 9 to financial assets and liabilities below:***

*Investments held at fair value through profit or loss*

The Company's investments were previously held at fair value through profit or loss under IAS 39. In terms of IFRS 9, the investment in its entirety continues to be held at fair value through profit or loss.

Therefore there is no change in the recognition or measurement of investments held at fair value through profit or loss.

*Trade and other receivables and cash and cash equivalents*

Trade and other receivables and cash and cash equivalents were previously measured at amortised cost under IAS 39. Under IFRS 9 assets can be classified under amortised cost under the following conditions:

- \_ the assets must be held in a business model whose objective is to collect contractual cash flows, i.e. "held to collect";
- and
- the contractual cash flows must represent solely payment of principal and interest on the principal amount outstanding.

These assets by virtue of their nature meet the above conditions and will therefore continue to be held at amortised cost under IFRS 9. Therefore there is no change in the recognition or measurement of trade and other receivables and cash and cash equivalents.

**Guaranteed Investment Products 1 PCC Limited**  
**Notes to the Financial Statements**  
**For the year ended 31 March 2019**

**1 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES**

*Trade and other payables*

Under IAS 39, trade and other payables were measured at amortised cost. This does not change with the application of IFRS 9.

IFRS 9 has been applied retrospectively by the Group and did not result in a change to the classification or measurement of financial instruments as outlined.

**2 CRITICAL ACCOUNTING ESTIMATES AND JUDGEMENTS**

In preparing these financial statements, the Board has made critical accounting estimates and judgements. The resulting accounting estimates will, by definition, seldom equal the related actual results. The estimates and judgements that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities after the financial period relate to the fair valuation of the derivative financial instruments as outlined below:

**(a) Accounting estimates**

**Fair value of derivative financial instruments**

The Company holds investments which are tailored to meet the Company's needs. As the investments are not traded in an active market, the fair value of such instruments is determined by using valuation techniques, the inputs are described in Note 4. The fair value is calculated monthly by the "Investment Advisor" (or any other party to a Plan Investment, save for the Company)). As at the reporting date, an independent check of the valuations of the investments is performed by Future Value Consultants (the "Valuation Agent"), an independent third party.

**(b) Going concern**

The Company has entered into an arrangement with the Investment Advisor whereby, save for its own fee and any fee payable to the Marketing Agent, the Investment Advisor shall meet all costs and expenses relating to the establishment, launch and operation of the Company, the Cells and the cost of listing any Shares of the Cells on the TISE.

After making enquiries, the directors have a reasonable expectation that the Company has adequate resources to continue in operational existence in the foreseeable future and is well placed to manage its business risks successfully. It is the board of directors' judgement that it is appropriate to adopt the going concern basis in preparing these financial statements as the board recognise that the counterparty to each investment held for each protected cell, the shareholders' guarantor for each protected cell and the "Investment Advisor" are all ultimately owned by Santander (UK) Plc., which, at the date of this report has a credit rating of Aa3 as rated by Moody's.

The Company has seen a number of its cells, each of which had a fixed life, redeem during the period. Additionally, in the course of the period, the Investment Advisor advised and the Board decided that it did not intend to launch any new cells. The last cell in the Company is due to mature at the end of December, 2020.

**Guaranteed Investment Products 1 PCC Limited**  
**Notes to the Financial Statements**  
**For the year ended 31 March 2019 (continued)**

**3 NET ASSET VALUE PER SHARE**

	As at 31 March 2019			As at 31 March 2018		
	Net assets attributable to holders of Shares	Shares in issue	NAV per Share	Net assets attributable to holders of Shares	Shares in issue	NAV per Share
	GBP	Note 6	Pence	GBP	Note 6	Pence
Cell 224	-	-	-	7,243,553	5,596,068	129.44
Cell 226	-	-	-	10,301,334	6,873,972	149.86
Cell 228	-	-	-	7,145,498	4,770,981	149.77
Cell 230	-	-	-	10,306,598	6,897,275	149.43
Cell 232	-	-	-	23,390,743	16,877,656	138.59
Cell 234	-	-	-	3,894,039	3,507,511	111.02
Cell 236	-	-	-	32,691,342	28,336,086	115.37
Cell 238	-	-	-	663,635	589,374	112.60
Cell 240	20,630,187	18,773,489	109.89	20,519,423	18,773,489	109.30
Cell 242	9,072,289	8,274,616	109.64	9,015,194	8,274,616	108.95
Cell 244	11,967,404	11,138,686	107.44	11,919,508	11,138,686	107.01
Cell 246	-	-	-	14,803,572	13,823,487	107.09
Cell 247	16,786,420	15,180,340	110.58	16,487,367	15,180,340	108.61
Cell 248	8,160,773	6,697,942	121.84	7,759,566	6,697,942	115.85
Cell 249	7,906,102	6,629,855	119.25	7,575,272	6,629,855	114.26
Cell 250	11,490,024	10,163,666	113.05	11,171,902	10,163,666	109.92
Cell 251	21,414,885	18,780,045	114.03	20,746,316	18,780,045	110.47
Cell 252	73,742,909	59,739,881	123.44	69,322,158	59,739,881	116.04
Cell 253	63,280,692	50,186,924	126.09	59,235,626	50,186,924	118.03
Cell 254	39,174,281	31,503,242	124.35	36,792,636	31,503,242	116.79
Cell 255	-	-	-	33,433,430	29,579,253	113.03
Cell 256	39,173,901	33,703,778	116.23	36,888,785	33,703,778	109.45
Cell 257	-	-	-	20,921,772	19,406,152	107.81
Cell 258	7,211,782	6,350,636	113.56	6,857,417	6,350,636	107.98
Cell 259	28,109,306	24,111,602	116.58	26,522,762	24,111,602	110.00
Cell 260	35,376,691	31,067,613	113.87	33,754,962	31,067,613	108.65
Cell 261	20,475,917	17,882,897	114.50	19,651,516	17,882,897	109.89
Cell 262	39,897,866	34,045,453	117.19	38,202,403	34,045,453	112.21
Cell 263	48,507,696	40,876,124	118.67	45,601,404	40,876,124	111.56
Cell 264	33,422,585	29,058,064	115.02	31,618,079	29,058,064	108.81
Cell 265	29,819,813	26,123,358	114.15	28,471,848	26,123,358	108.99
Cell 266	3,612,888	3,362,703	107.44	3,475,354	3,362,703	103.35
Cell 267	8,795,091	8,312,155	105.81	8,496,685	8,312,155	102.22
Cell 268	4,148,025	3,969,402	104.50	4,026,958	3,969,402	101.45
Cell 269	18,765,498	18,336,426	102.34	18,305,254	18,336,426	99.83
Cell 270	12,448,343	12,252,302	101.60	12,135,907	12,252,302	99.05
	<u>613,391,368</u>	<u>526,521,199</u>		<u>749,349,816</u>	<u>662,779,014</u>	
Management Fund	2	2		2	2	
<b>TOTAL</b>	<u><b>613,391,370</b></u>	<u><b>526,521,201</b></u>		<u><b>749,349,818</b></u>	<u><b>662,779,016</b></u>	
Non Current	538,868,192			584,554,300		
Current	<u>74,523,176</u>			<u>164,795,516</u>		
	<u>613,391,368</u>			<u>749,349,816</u>		

**Guaranteed Investment Products 1 PCC Limited**  
**Notes to the Financial Statements**  
**For the year ended 31 March 2019 (continued)**

**4 INVESTMENTS**

	<b>As at 31 March 2019 Total GBP</b>	<b>As at 31 March 2018 Total GBP</b>
Opening portfolio cost	653,830,805	730,021,320
Opening unrealised gain on valuation	95,519,011	97,671,100
Opening valuation	<u>749,349,816</u>	<u>827,692,420</u>
Proceeds of maturity of financial assets	(168,297,948)	(88,701,318)
Realised gain for the period	34,817,593	12,510,803
Unrealised gain for the period	28,837,067	11,764,171
Unrealised loss for the period	(31,315,160)	(13,916,260)
<b>Total</b>	<u><b>613,391,368</b></u>	<u><b>749,349,816</b></u>
Closing portfolio cost	520,350,450	653,830,805
Closing unrealised gain on valuation	93,040,918	95,519,011
<b>Closing valuation</b>	<u><b>613,391,368</b></u>	<u><b>749,349,816</b></u>
<b>Minimum return</b>	530,673,069	664,375,619
<b>Value of derivative</b>	82,738,950	84,974,197
	<u><b>613,412,019</b></u>	<u><b>749,349,816</b></u>
<b>Non Current Investments</b>	538,868,192	584,554,300
<b>Current Investments</b>	74,523,176	164,795,516
	<u><b>613,391,368</b></u>	<u><b>749,349,816</b></u>

IFRS 13 requires fair value to be disclosed by the source of inputs, using a three-level hierarchy:

Quoted prices (unadjusted) in active markets for identical assets or liabilities (Level 1);

Inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly (as prices) or indirectly (derived from prices) (Level 2);

Inputs for the asset or liability that are not based on observable market data (unobservable inputs) (Level 3).

The Investments entered into by the Company are index linked and valued using a combination of cash flow modelling, Black Scholes and other relevant option models, as well as other conventional finance techniques, and take into account the following criteria:

- minimum and maximum return thresholds contracted by each cell at its inception date
- direct market data on the performance of the Index to which the relevant cell is linked
- indirect market data on the volatility related to the Index to which the relevant cell is linked
- time remaining until the maturity date of the cell
- any accrued interest receivable as at the valuation date
- direct market data on the interest yield curves
- discount rate derived from market data on the Counterparty's cost of capital

Carrying value of the investments is an approximation of the fair value.

**Guaranteed Investment Products 1 PCC Limited**  
**Notes to the Financial Statements**  
**For the year ended 31 March 2019 (continued)**

**4 INVESTMENTS (continued)**

The level in the fair value hierarchy within which the fair value measurement is categorised is determined on the basis of the lowest level input that is significant to the fair value in its entirety. If a fair value measurement uses significant unobservable inputs, or observable inputs that require significant adjustments based on unobservable inputs, then that measurement is deemed a level 3 measurement. Assessing the significance of a particular input to the fair value measurement in its entirety requires judgement, considering factors specific to the asset or liability. At year end, all investments held by the Company and net assets attributable to holders of shares, have been classified as Level 2 in accordance with the fair value hierarchy. The fair value measurement of investments uses inputs that are observable to determine the fair value of the investments. There have been no transfers between levels of the fair value hierarchy during the year.

**Other financial assets and liabilities**

For all other financial assets and liabilities, the carrying value is an approximation of fair value, including: receivables; cash and cash equivalents and other payables.

The Carrying value for net assets attributable to holders of protected cell is calculated with reference to the Net Asset Value of the Company. Net Asset value is calculated after the revaluation of the investments (Note 1d).

<b>5 RECEIVABLES</b>	<b>31 March 2019</b>	<b>31 March 2018</b>
	<b>GBP</b>	<b>GBP</b>
Sundry receivables	5,388	-

**6 SHARE CAPITAL**

The Company may issue an unlimited number of shares. Such shares may be issued as Cell Shares or Nominal Shares (or share of any other denomination as the directors may determine).

**31 March 2019**

	Number of Shares issued as at 31 March 2018	Number of Shares Issued / (Redeemed)	Number of Shares issued as at 31 March 2019
<b>Allotted, called-up and fully paid Guaranteed Shares</b>			
Cell 224	5,596,068	(5,596,068)	-
Cell 226	6,873,972	(6,873,972)	-
Cell 228	4,770,981	(4,770,981)	-
Cell 230	6,897,275	(6,897,275)	-
Cell 232	16,877,656	(16,877,656)	-
Cell 234	3,507,511	(3,507,511)	-
Cell 236	28,336,086	(28,336,086)	-
Cell 238	589,374	(589,374)	-
Cell 240	18,773,489	-	18,773,489
Cell 242	8,274,616	-	8,274,616
Cell 244	11,138,686	-	11,138,686
Cell 246	13,823,487	(13,823,487)	-
Cell 247	15,180,340	-	15,180,340
Cell 248	6,697,942	-	6,697,942
Cell 249	6,629,855	-	6,629,855
Cell 250	10,163,666	-	10,163,666
Cell 251	18,780,045	-	18,780,045
Cell 252	59,739,881	-	59,739,881

**Guaranteed Investment Products 1 PCC Limited**  
**Notes to the Financial Statements**  
**For the year ended 31 March 2019 (continued)**

**6 SHARE CAPITAL (continued)**

	Number of Shares issued as at 31 March 2018	Number of Shares Issued / (Redeemed)	Number of Shares issued as at 31 March 2019
<b>Allotted, called-up and fully paid Guaranteed Shares</b>			
Cell 253	50,186,924	-	50,186,924
Cell 254	31,503,242	-	31,503,242
Cell 255	29,579,253	(29,579,253)	-
Cell 256	33,703,778	-	33,703,778
Cell 257	19,406,152	(19,406,152)	-
Cell 258	6,350,636	-	6,350,636
Cell 259	24,111,602	-	24,111,602
Cell 260	31,067,613	-	31,067,613
Cell 261	17,882,897	-	17,882,897
Cell 262	34,045,453	-	34,045,453
Cell 263	40,876,124	-	40,876,124
Cell 264	29,058,064	-	29,058,064
Cell 265	26,123,358	-	26,123,358
Cell 266	3,362,703	-	3,362,703
Cell 267	8,312,155	-	8,312,155
Cell 268	3,969,402	-	3,969,402
Cell 269	18,336,426	-	18,336,426
Cell 270	12,252,302	-	12,252,302
Management Shares	2	-	2
<b>TOTAL</b>	<b>662,779,016</b>	<b>(136,257,815)</b>	<b>526,521,201</b>

	Fund GBP	Management Shares GBP	TOTAL GBP
<b>2019 Authorised</b>			
10,000,000,000 Unclassified Shares of 0.0001p each	100,000	-	100,000
100 Management Shares of £1 each	-	100	100
	<b>100,000</b>	<b>100</b>	<b>100,100</b>

**31 March 2018**

	Number of Shares issued as at 31 March 2017	Number of Shares Issued / (Redeemed)	Number of Shares issued as at 31 March 2018
<b>Allotted, called-up and fully paid Guaranteed Shares</b>			
Cell 199	7,771,199	(7,771,199)	-
Cell 207	3,938,584	(3,938,584)	-
Cell 209	7,142,981	(7,142,981)	-
Cell 211	2,804,294	(2,804,294)	-
Cell 213	3,741,147	(3,741,147)	-
Cell 215	3,908,289	(3,908,289)	-
Cell 218	16,081,753	(16,081,753)	-
Cell 220	880,420	(880,420)	-

**Guaranteed Investment Products 1 PCC Limited**  
**Notes to the Financial Statements**  
**For the year ended 31 March 2019 (continued)**

**6 SHARE CAPITAL (continued)**

	Number of Shares issued as at 31 March 2017	Number of Shares Issued / (Redeemed)	Number of Shares issued as at 31 March 2018
<b>Allotted, called-up and fully paid Guaranteed Shares</b>			
Cell 222	2,430,040	(2,430,040)	-
Cell 224	5,596,068	-	5,596,068
Cell 226	6,873,972	-	6,873,972
Cell 228	4,770,981	-	4,770,981
Cell 230	6,897,275	-	6,897,275
Cell 232	16,877,656	-	16,877,656
Cell 234	3,507,511	-	3,507,511
Cell 236	28,336,086	-	28,336,086
Cell 238	589,374	-	589,374
Cell 240	18,773,489	-	18,773,489
Cell 241	5,442,192	(5,442,192)	-
Cell 242	8,274,616	-	8,274,616
Cell 243	11,966,257	(11,966,257)	-
Cell 244	11,138,686	-	11,138,686
Cell 245	12,122,138	(12,122,138)	-
Cell 246	13,823,487	-	13,823,487
Cell 247	15,180,340	-	15,180,340
Cell 248	6,697,942	-	6,697,942
Cell 249	6,629,855	-	6,629,855
Cell 250	10,163,666	-	10,163,666
Cell 251	18,780,045	-	18,780,045
Cell 252	59,739,881	-	59,739,881
Cell 253	50,186,924	-	50,186,924
Cell 254	31,503,242	-	31,503,242
Cell 255	29,579,253	-	29,579,253
Cell 256	33,703,778	-	33,703,778
Cell 257	19,406,152	-	19,406,152
Cell 258	6,350,636	-	6,350,636
Cell 259	24,111,602	-	24,111,602
Cell 260	31,067,613	-	31,067,613
Cell 261	17,882,897	-	17,882,897
Cell 262	34,045,453	-	34,045,453
Cell 263	40,876,124	-	40,876,124
Cell 264	29,058,064	-	29,058,064
Cell 265	26,123,358	-	26,123,358
Cell 266	3,362,703	-	3,362,703
Cell 267	8,312,155	-	8,312,155
Cell 268	3,969,402	-	3,969,402
Cell 269	18,336,426	-	18,336,426
Cell 270	12,252,302	-	12,252,302
<b>Management Shares</b>	<b>2</b>	<b>-</b>	<b>2</b>
<b>TOTAL</b>	<b>741,008,310</b>	<b>(78,229,294)</b>	<b>662,779,016</b>

**Guaranteed Investment Products 1 PCC Limited**  
**Notes to the Financial Statements**  
**For the year ended 31 March 2019 (continued)**

**6 SHARE CAPITAL (continued)**

**31 March 2019**

	Issued Share capital as at 31 March 2018	Shares Issued / (Redeemed)	Issued Share capital as at 31 March 2019
<b>Allotted, called-up and fully paid Guaranteed Shares</b>	<b>GBP</b>	<b>GBP</b>	<b>GBP</b>
Cell 224	6	(6)	-
Cell 226	7	(7)	-
Cell 228	5	(5)	-
Cell 230	7	(7)	-
Cell 232	17	(17)	-
Cell 234	4	(4)	-
Cell 236	28	(28)	-
Cell 238	1	(1)	-
Cell 240	19	-	19
Cell 242	9	-	9
Cell 244	11	-	11
Cell 246	14	(14)	-
Cell 247	15	-	15
Cell 248	7	-	7
Cell 249	7	-	7
Cell 250	10	-	10
Cell 251	19	-	19
Cell 252	60	-	60
Cell 253	50	-	50
Cell 254	32	-	32
Cell 255	30	(30)	-
Cell 256	34	-	34
Cell 257	19	(19)	-
Cell 258	6	-	6
Cell 259	24	-	24
Cell 260	31	-	31
Cell 261	18	-	18
Cell 262	34	-	34
Cell 263	41	-	41
Cell 264	29	-	29
Cell 265	26	-	26
Cell 266	3	-	3
Cell 267	8	-	8
Cell 268	4	-	4
Cell 269	18	-	18
Cell 270	12	-	12
Management Shares	2	-	2
<b>TOTAL</b>	<b>667</b>	<b>(138)</b>	<b>529</b>

**Guaranteed Investment Products 1 PCC Limited**  
**Notes to the Financial Statements**  
**For the year ended 31 March 2019 (continued)**

**6 SHARE CAPITAL (continued)**

**31 March 2018**

	Issued Share capital as at 31 March 2017	Shares Issued / (Redeemed)	Issued Share capital as at 31 March 2018
<b>Allotted, called-up and fully paid Guaranteed Shares</b>	<b>GBP</b>	<b>GBP</b>	<b>GBP</b>
Cell 199	8	(8)	-
Cell 207	4	(4)	-
Cell 209	7	(7)	-
Cell 211	3	(3)	-
Cell 213	4	(4)	-
Cell 215	4	(4)	-
Cell 218	16	(16)	-
Cell 220	1	(1)	-
Cell 222	2	(2)	-
Cell 224	6	-	6
Cell 226	7	-	7
Cell 228	5	-	5
Cell 230	7	-	7
Cell 232	17	-	17
Cell 234	4	-	4
Cell 236	28	-	28
Cell 238	1	-	1
Cell 240	19	-	19
Cell 241	5	(5)	-
Cell 242	9	-	9
Cell 243	12	(12)	-
Cell 244	11	-	11
Cell 245	12	(12)	-
Cell 246	14	-	14
Cell 247	15	-	15
Cell 248	7	-	7
Cell 249	7	-	7
Cell 250	10	-	10
Cell 251	19	-	19
Cell 252	60	-	60
Cell 253	50	-	50
Cell 254	32	-	32
Cell 255	30	-	30
Cell 256	34	-	34
Cell 257	19	-	19
Cell 258	6	-	6
Cell 259	24	-	24
Cell 260	31	-	31
Cell 261	18	-	18
Cell 262	34	-	34
Cell 263	41	-	41
Cell 264	29	-	29
Cell 265	26	-	26
Cell 266	3	-	3
Cell 267	8	-	8

**Guaranteed Investment Products 1 PCC Limited**  
**Notes to the Financial Statements**  
**For the year ended 31 March 2019 (continued)**

**6 SHARE CAPITAL (continued)**

	Issued Share capital as at 31 March 2017	Shares Issued / (Redeemed)	Issued Share capital as at 31 March 2018
	GBP	GBP	GBP
<b>Allotted, called-up and fully paid Guaranteed Shares</b>			
Cell 268	4	-	4
Cell 269	18	-	18
Cell 270	12	-	12
Management Shares	2	-	2
<b>TOTAL</b>	<b>745</b>	<b>(78)</b>	<b>667</b>

Management shares are not entitled to receive and shall not participate in any dividends or other distributions out of the profits of the Company. The holders of the Management shares shall be entitled to receive notice of and to attend and vote at general meetings. The Management shares are not redeemable.

Shares held in Cells 240, 242, 244, 247 to 254, 256, 258 to 270 shall not be entitled to receive and shall not participate in any dividends or other distributions out of the profits of the Company. On their respective redemption dates the holders of Shares shall be entitled to an amount equal to the Net Asset Value per Share. As disclosed in the Securities Note for each cell, the Shares of the relevant cell will be compulsorily redeemed by the Company on their respective Redemption Dates. The holders of the Shares shall be entitled to receive notice of and to attend and vote at separate general meetings in relation to that Share.

**7 SHARE PREMIUM**

**31 March 2019**

	Share premium as at 31 March 2018	Share premium on Protected Cell Guaranteed Shares	Share premium as at 31 March 2019
	GBP	GBP	GBP
Cell 224	5,593,806	(5,593,806)	-
Cell 226	6,871,727	(6,871,727)	-
Cell 228	4,769,963	(4,769,963)	-
Cell 230	6,895,605	(6,895,605)	-
Cell 232	16,870,149	(16,870,149)	-
Cell 234	3,506,400	(3,506,400)	-
Cell 236	28,325,083	(28,325,083)	-
Cell 238	589,290	(589,290)	-
Cell 240	18,769,038	-	18,769,038
Cell 242	8,273,472	-	8,273,472
Cell 244	11,137,379	-	11,137,379
Cell 246	13,822,132	(13,822,132)	-
Cell 247	15,177,775	-	15,177,775
Cell 248	6,697,719	-	6,697,719
Cell 249	6,629,621	-	6,629,621
Cell 250	10,162,691	-	10,162,691
Cell 251	18,776,546	-	18,776,546

**Guaranteed Investment Products 1 PCC Limited**  
**Notes to the Financial Statements**  
**For the year ended 31 March 2019 (continued)**

**7 SHARE PREMIUM (continued)**

	Share premium as at 31 March 2018	Share premium on Protected Cell Guaranteed Shares	Share premium as at 31 March 2019
	<b>GBP</b>	<b>GBP</b>	<b>GBP</b>
Cell 252	59,724,029	-	59,724,029
Cell 253	50,174,266	-	50,174,266
Cell 254	31,497,602	-	31,497,602
Cell 255	29,573,346	(29,573,346)	-
Cell 256	33,693,467	-	33,693,467
Cell 257	19,399,343	(19,399,343)	-
Cell 258	6,348,434	-	6,348,434
Cell 259	24,107,260	-	24,107,260
Cell 260	31,061,165	-	31,061,165
Cell 261	17,879,200	-	17,879,200
Cell 262	34,037,207	-	34,037,207
Cell 263	40,861,908	-	40,861,908
Cell 264	29,049,296	-	29,049,296
Cell 265	22,471,468	-	22,471,468
Cell 266	3,362,133	-	3,362,133
Cell 267	8,311,703	-	8,311,703
Cell 268	3,969,271	-	3,969,271
Cell 269	18,333,337	-	18,333,337
Cell 270	12,248,747	-	12,248,747
<b>TOTAL</b>	<b>658,971,578</b>	<b>(136,216,844)</b>	<b>522,754,734</b>

**31 March 2018**

	Share premium as at 31 March 2017	Share premium on Protected Cell Guaranteed Shares	Share premium as at 31 March 2018
	<b>GBP</b>	<b>GBP</b>	<b>GBP</b>
Cell 199	7,769,089	(7,769,089)	-
Cell 207	3,937,235	(3,937,235)	-
Cell 209	7,140,442	(7,140,442)	-
Cell 211	2,803,602	(2,803,602)	-
Cell 213	3,740,064	(3,740,064)	-
Cell 215	3,907,535	(3,907,535)	-
Cell 218	16,075,949	(16,075,949)	-
Cell 220	880,190	(880,190)	-
Cell 222	2,429,600	(2,429,600)	-
Cell 224	5,593,806	-	5,593,806
Cell 226	6,871,727	-	6,871,727
Cell 228	4,769,963	-	4,769,963
Cell 230	6,895,605	-	6,895,605
Cell 232	16,870,149	-	16,870,149
Cell 234	3,506,400	-	3,506,400
Cell 236	28,325,083	-	28,325,083

**Guaranteed Investment Products 1 PCC Limited**  
**Notes to the Financial Statements**  
**For the year ended 31 March 2019 (continued)**

**7 SHARE PREMIUM (continued)**

	Share premium as at 31 March 2017	Share premium on Protected Cell Guaranteed Shares	Share premium as at 31 March 2018
	GBP	GBP	GBP
Cell 238	589,290	-	589,290
Cell 240	18,769,038	-	18,769,038
Cell 241	5,442,187	(5,442,187)	-
Cell 242	8,273,472	-	8,273,472
Cell 243	11,966,245	(11,966,245)	-
Cell 244	11,137,379	-	11,137,379
Cell 245	12,122,126	(12,122,126)	-
Cell 246	13,822,132	-	13,822,132
Cell 247	15,177,775	-	15,177,775
Cell 248	6,697,719	-	6,697,719
Cell 249	6,629,621	-	6,629,621
Cell 250	10,162,691	-	10,162,691
Cell 251	18,776,546	-	18,776,546
Cell 252	59,724,029	-	59,724,029
Cell 253	50,174,266	-	50,174,266
Cell 254	31,497,602	-	31,497,602
Cell 255	29,573,346	-	29,573,346
Cell 256	33,693,467	-	33,693,467
Cell 257	19,399,343	-	19,399,343
Cell 258	6,348,434	-	6,348,434
Cell 259	24,107,260	-	24,107,260
Cell 260	31,061,165	-	31,061,165
Cell 261	17,879,200	-	17,879,200
Cell 262	34,037,207	-	34,037,207
Cell 263	40,861,908	-	40,861,908
Cell 264	29,049,296	-	29,049,296
Cell 265	22,471,468	-	22,471,468
Cell 266	3,362,133	-	3,362,133
Cell 267	8,311,703	-	8,311,703
Cell 268	3,969,271	-	3,969,271
Cell 269	18,333,337	-	18,333,337
Cell 270	12,248,747	-	12,248,747
<b>TOTAL</b>	<b>737,185,842</b>	<b>(78,214,264)</b>	<b>658,971,578</b>

	Mar-19	Mar-18
<b>Movement in Other Reserves on redemption of shares</b>		
Opening Balance	90,377,572	90,487,760
On redemption	(32,080,966)	(10,468,902)
Profit for year	32,339,500	10,358,714
Carried Forward	90,636,106	90,377,572

**Guaranteed Investment Products 1 PCC Limited**  
**Notes to the Financial Statements**  
**For the year ended 31 March 2019 (continued)**

**8 FINANCIAL RISK MANAGEMENT OBJECTIVES AND POLICIES**

Risk is inherent in the Company's activities, but it is managed through a process of ongoing identification, measurement, monitoring and, where possible, mitigation of risks. A risk matrix has been established by the Board and is reviewed quarterly. The main risks arising from the Company's financial instruments are market price risk, credit risk and liquidity risk. The Board regularly reviews and agrees policies for managing each of these risks and these are summarised below. There is no significant interest rate risk or foreign exchange risk as none of the Company's significant financial instruments are interest bearing and all exposures or positions are GBP denominated.

**(a) Market Price Risk**

Market price risk arises mainly from uncertainty about future prices of financial instruments held. It represents the potential loss the Company might suffer through holding market positions in the face of price movements. The principal components of market risk for the Company relates to the risk of adverse movements in the value of the market price of the index underlying each Cell Investment Plan. The Investment Counterparty actively monitors market prices and reports to the Board as to the appropriateness of the prices used for valuation purposes. All cells have a minimum return at maturity, although this value is not assured during the life of the Cell prior to maturity.

*Price sensitivity*

If market prices as at 31 March 2019 had been 10% higher or lower, and assuming these values were to remain unchanged through to the end of the life of the Cells, with all the other variables held constant, the increase or decrease in net assets attributable to holders of Shares on the Maturity Date would have been as stated below, arising due to the increase or decrease in the fair value of financial assets at fair value through profit or loss. For most of the Cells, the effect of movements in the FTSE100 Index have been used in these sensitivity calculations as the FTSE100 Index is considered to be the market whose movements would have the greatest effect on the market price of each Cell's investments.

This can be summarised in the following table:

Index	31 March 2019	
	Number of Cells	Total Market Value GBP
FTSE 100	25	<u>613,391,368</u>
<b>TOTAL</b>		<u><u>613,391,368</u></u>
Index	02 April 2018	
	Number of Cells	Total Market Value GBP
FTSE 100	36	<u>749,349,816</u>
<b>TOTAL</b>		<u><u>749,349,816</u></u>

**Guaranteed Investment Products 1 PCC Limited**  
**Notes to the Financial Statements**  
**For the year ended 31 March 2019 (continued)**

**8 FINANCIAL RISK MANAGEMENT OBJECTIVES AND POLICIES (continued)**

**(a) Market Price Risk (continued)**

The European Regulation on indexes used as benchmarks in financial instruments and financial contracts or to measure the performance of investment funds (the EU BMR) applies from 1 January 2018.

The EU BMR introduces a common framework to ensure the accuracy and integrity of indexes used as benchmarks in the European Union. The EU BMR applies to the:

- provision of benchmarks
- contribution of input data to a benchmark
- use of a benchmark within the European Union

Under the EU BMR, only the following types of benchmarks may be used by supervised entities within the European Union:

- Benchmarks that are provided by EU based administrators who have been granted authorisation or registration under the EU BMR and who are identified on the register to be maintained by the European Securities and Markets Association (ESMA)
- Benchmarks that have been entered onto the ESMA register which are provided by third country administrators who have either:
  - satisfied the requirements for equivalence, or
  - acquired recognition under the EU BMR, or
  - successfully sought endorsement from an EU authorised or registered administrator or other supervised entity for specific benchmarks.

The UK's Financial Conduct Authority (FCA) has granted FTSE International Limited authorization as a benchmark administrator under the European benchmark regulation (EU BMR). FTSE International Limited is listed on the FCA register and appears on the ESMA register for administrators.

The following table details each Cell's sensitivity to a 10% increase and decrease in the index levels affecting its investments.

Cell	Increase in net assets attributable to holders of Shares		Decrease in net assets attributable to holders of Shares	
	Year ended 31 March 2019	Year ended 31 March 2018	Year ended 31 March 2019	Year ended 31 March 2018
	GBP	GBP	GBP	GBP
Cell 224	-	33,177	-	(16,588)
Cell 230	-	81,714	-	(4,085)
Cell 232	-	817,577	-	(81,679)
Cell 234	-	28,512	-	(44,008)
Cell 236	-	1,387,635	-	(1,144,223)
Cell 238	-	13,874	-	(14,934)
Cell 240	20,651	102,074	20,651	(143,198)
Cell 242	221	37,479	-	(51,099)
Cell 244	225,273	79,097	(10,484)	(86,932)
Cell 246	-	67,281	-	(117,076)
Cell 247	1,379,719	583,513	(789,629)	(434,182)
Cell 248	985,472	576,486	(874,471)	(340,256)
Cell 249	919,808	516,166	(750,416)	(314,358)
Cell 250	1,273,323	635,379	(850,241)	(423,000)
Cell 251	2,281,278	1,207,571	(1,626,609)	(777,344)
Cell 252	3,398,580	3,865,643	(4,986,538)	(1,805,615)

**Guaranteed Investment Products 1 PCC Limited**  
**Notes to the Financial Statements**  
**For the year ended 31 March 2019 (continued)**

**8 FINANCIAL RISK MANAGEMENT OBJECTIVES AND POLICIES (continued)**

**(a) Market Price Risk (continued)**

	Increase in net assets attributable to holders of Shares		Decrease in net assets attributable to holders of Shares	
	Year ended 31 March 2019	Year ended 31 March 2018	Year ended 31 March 2019	Year ended 31 March 2018
Cell 253	2,212,488	3,066,415	(3,488,163)	(1,374,448)
Cell 254	1,118,209	1,716,218	(1,822,392)	(745,385)
Cell 255	-	1,236,344	-	(321,111)
Cell 256	1,500,050	1,503,625	(2,009,448)	(747,930)
Cell 257	-	748,326	-	(350,284)
Cell 258	214,675	223,495	(294,906)	(110,135)
Cell 259	1,024,052	1,066,126	(1,406,774)	(525,373)
Cell 260	706,866	1,009,369	(1,119,212)	(448,506)
Cell 261	268,819	505,868	(475,981)	(206,441)
Cell 262	598,800	1,105,995	(1,062,781)	(453,041)
Cell 263	2,397,342	2,113,970	(2,811,130)	(1,085,445)
Cell 264	1,903,051	1,360,989	(1,913,290)	(759,110)
Cell 265	570,831	846,046	(918,072)	(371,665)
Cell 266	130,106	84,346	(126,793)	(48,729)
Cell 267	254,159	163,384	(249,299)	(94,734)
Cell 268	100,840	61,171	(95,135)	(36,430)
Cell 269	325,493	181,589	(284,201)	(111,403)
Cell 270	326,050	157,968	(242,424)	(104,430)
Total	24,136,156	27,184,422	(28,187,738)	(13,693,177)

**(b) Credit Risk**

Credit risk is the risk that the Investment Counterparty does not meet a commitment that it has entered into with the Company. At the date of this report all investments were issued by one counterparty, being Santander UK plc ("Santander"), which held a credit rating of Aa3 using the Moody's credit ratings. Such concentration of risk is monitored by the directors regularly observing the credit rating of Santander. The maximum credit risk of the Company in relation to Santander as at 29 March 2019 is £613,391,368 (31 March 2018 : £749,349,816).

The allotments from new investees during a cell's offer period are held with only one bank, being Royal Bank of Scotland International Limited, the ultimate parent company of which holds a long term credit rating of Baa2 using the Moody's credit rating system. The maximum credit risk of the Company in relation to the Royal Bank of Scotland International Limited as at 29 March 2019 is £119,612 (31 March 2018 : £125,000).

All returns on the Equity Index Swap Transactions have a guaranteed minimum level and a maximum level based on the performance of the FTSE 100 Index over the life of the Cell, as relevant and as identified in Note 8a. The table below sets out the guaranteed and maximum amounts of each cell at maturity date together with an "undiscounted value".

The NAV of each cell is disclosed in Note 3 and is equal to the fair value of each cell's investment. This fair value is a discounted amount, allowing for the time value of money up to the expected date of maturity of the cell and its investment. In order to allow a direct comparison between guaranteed and maximum amount (which are not discounted) an "undiscounted value" has been calculated which excludes the effect of the time value of money from the calculation of fair value in Note 3.

**Guaranteed Investment Products 1 PCC Limited**  
**Notes to the Financial Statements**  
**For the year ended 31 March 2019 (continued)**

**8 FINANCIAL RISK MANAGEMENT OBJECTIVES AND POLICIES (continued)**

**(b) Credit Risk (continued)**

**31 March 2019**

Cell	Maturity Date	Undiscounted	Redemption Amount	
		Value	Guaranteed	Maximum
Cell 240	04 April 2019	20,659,260	20,650,838	Note 7bi
Cell 242	06 June 2019	9,099,352	9,102,078	Note 7bi
Cell 244	21 August 2019	12,039,322	12,029,781	16,708,029
Cell 247	12 December 2019	16,955,860	15,939,357	22,770,510
Cell 248	30 January 2020	8,247,316	6,865,391	10,046,913
Cell 249	13 March 2020	8,004,000	6,828,751	9,944,783
Cell 250	08 May 2020	11,662,804	10,417,758	15,245,499
Cell 251	18 June 2020	21,766,545	19,249,546	28,170,068
Cell 252	27 August 2020	75,032,953	61,233,481	81,246,374
Cell 253	06 November 2020	64,508,031	51,441,597	68,254,217
Cell 254	23 December 2020	40,008,926	32,290,823	42,214,344
Cell 256	21 December 2020	40,057,235	34,546,372	43,140,836
Cell 258	16 November 2020	7,369,162	6,509,402	7,747,776
Cell 259	16 November 2020	28,706,834	24,714,392	30,621,735
Cell 260	23 December 2020	36,199,794	31,844,303	37,591,812
Cell 261	10 December 2020	20,938,047	18,329,969	21,459,476
Cell 262	12 November 2020	40,738,796	34,896,589	41,535,453
Cell 263	29 December 2020	49,592,330	41,898,027	55,182,767
Cell 264	21 December 2020	34,177,057	29,784,516	39,228,386
Cell 265	11 December 2020	30,495,958	26,776,442	31,609,263
Cell 266	31 December 2020	3,702,116	3,446,771	4,035,244
Cell 267	21 December 2020	9,012,265	8,519,959	9,642,100
Cell 268	02 November 2020	4,243,802	4,068,637	4,485,424
Cell 269	31 December 2020	19,252,049	18,794,837	20,170,069
Cell 270	17 December 2020	12,762,212	12,313,564	13,722,578

**31 March 2018**

Cell	Maturity Date	Undiscounted	Redemption Amount	
		Value	Guaranteed	Maximum
Cell 224	10 April 2018	7,245,923	6,043,753	7,834,495
Cell 226	10 May 2018	10,311,274	6,908,342	10,310,958
Cell 228	05 June 2018	7,156,155	4,794,836	7,156,472
Cell 230	06 August 2018	10,336,022	6,931,761	10,345,913
Cell 232	11 October 2018	23,500,283	16,962,044	23,628,718
Cell 234	06 December 2018	3,926,263	3,893,337	Note 7bi
Cell 236	07 January 2019	32,979,659	31,169,695	39,670,520
Cell 238	05 March 2019	670,894	654,205	854,592
Cell 240	04 April 2019	20,770,672	20,650,838	Note 7bi
Cell 242	06 June 2019	9,147,475	9,102,078	Note 7bi
Cell 244	21 August 2019	12,129,132	12,029,781	16,708,029
Cell 246	03 January 2019	14,940,064	14,860,249	20,735,231
Cell 247	12 December 2019	16,840,571	15,939,357	22,770,510

**Guaranteed Investment Products 1 PCC Limited**  
**Notes to the Financial Statements**  
**For the year ended 31 March 2019 (continued)**

**8 FINANCIAL RISK MANAGEMENT OBJECTIVES AND POLICIES (continued)**

**(b) Credit Risk (continued)**

Cell	Maturity Date	Undiscounted Value	Redemption Amount	
			Guaranteed	Maximum
Cell 248	30 January 2020	7,926,145	6,865,391	10,046,913
Cell 249	13 March 2020	7,753,864	6,828,751	9,944,783
Cell 250	08 May 2020	11,471,831	10,417,758	15,245,499
Cell 251	18 June 2020	21,340,177	19,249,546	28,170,068
Cell 252	27 August 2020	71,428,183	61,233,481	81,246,374
Cell 253	06 November 2020	61,194,035	51,441,597	68,254,217
Cell 254	23 December 2020	38,109,403	32,290,823	42,214,344
Cell 255	03 January 2019	33,711,909	30,318,734	34,311,933
Cell 256	21 December 2020	38,284,293	34,546,372	43,140,836
Cell 257	21 March 2019	21,154,070	19,891,306	22,123,013
Cell 258	16 November 2020	7,108,024	6,509,402	7,747,776
Cell 259	16 November 2020	27,474,248	24,714,392	30,621,735
Cell 260	23 December 2020	35,053,520	31,844,303	37,591,812
Cell 261	10 December 2020	20,382,964	18,329,969	21,459,476
Cell 262	12 November 2020	39,542,150	34,896,589	41,535,453
Cell 263	29 December 2020	47,312,234	41,898,027	55,182,767
Cell 264	21 December 2020	32,811,481	29,784,516	39,228,386
Cell 265	11 December 2020	29,541,806	26,776,442	31,609,263
Cell 266	31 December 2020	3,616,096	3,446,771	4,035,244
Cell 267	21 December 2020	8,839,920	8,519,959	9,642,100
Cell 268	02 November 2020	4,180,116	4,068,637	4,485,424
Cell 269	31 December 2020	19,072,707	18,794,837	20,170,069
Cell 270	17 December 2020	12,631,969	12,313,564	13,722,578

Note 7 bi Maturity Proceeds will be based on aggregated return of the FTSE Index over the Averaging Periods as defined in the individual term sheets.

At 31 March 2019 and 31 March 2018, all cash and receivables that are held with counter parties have been assessed for probability of default, as a result no loss allowance has been recognised based on 12 month expected credit losses as any such impairment would be wholly insignificant to the Company.

**(c) Liquidity Risk**

Liquidity risk is the risk that the Company will encounter difficulty in realising assets or otherwise raising funds to meet financial commitments. The only financial commitments of the Company are meeting ongoing expenses and these are paid out of monies provided by the "Investment Advisor", which are not assets of the Company.

The Company's liability to Shareholders to meet the redemption amount on Shares of each Cell is matched exactly to the maturity date of the Investments allocated to that Cell (Refer to 8(b) Credit Risk). Therefore, the Company, as a whole, and each Cell individually, has no liquidity mismatch.

Shareholders will be assured of receiving the Guaranteed Return in respect of their Shareholding on the relevant maturity date only if either:

i) The "Investment Advisor" satisfies its obligations under the Protected Cell Equity Index Derivative to pay the Company an amount at least equal in aggregate to the Guaranteed Return for their Shares on or around the relevant maturity date;

**Guaranteed Investment Products 1 PCC Limited**  
**Notes to the Financial Statements**  
**For the year ended 31 March 2019 (continued)**

**8 FINANCIAL RISK MANAGEMENT OBJECTIVES AND POLICIES (continued)**

**(c) Liquidity Risk (continued)**

ii) Santander Guarantee Company ("SGC"), a wholly owned direct subsidiary of Santander (UK) plc., satisfies its obligations under the Cell Guarantee Facility Agreement applicable to the Shares on the maturity date if Shareholders do not receive an amount at least equal to the Guaranteed Return in respect of their Shares held until they are redeemed on the maturity date and, if necessary, Santander (UK) plc. satisfies its obligations to SGC under the Conditional Share Subscription Agreement.

If the "Investment Advisor" were to fail to perform its obligations under the terms of the Financial Transactions and SGC were to default under the Cell Guarantee Facility Agreement applicable to the Shares, the Shareholders could lose some or all of their investment.

**(d) Capital Management**

The capital comprises of the net assets attributable to holders of shares of the Company. Capital is managed by entering into an investment which has agreed terms for each protected cell comprising of a guaranteed fixed amount and a growth amount depending on the performance of the underlying investment, (this is further explained in Note 8(b)), which is matched to the maturity of liabilities.

**9 ONGOING EXPENSES**

	<b>Year ended</b>	<b>Year ended</b>
	<b>31 March 2019</b>	<b>31 March 2018</b>
	<b>GBP</b>	<b>GBP</b>
Annual Fees	42,600	45,000
Audit Fees	31,750	51,412
Directors' Fees	100,085	68,483
Administration Fees	110,831	153,404
Registrar's Fees	6,181	8,270
Other Sundry Expenses	18,165	29,223
<b>TOTAL</b>	<b>309,612</b>	<b>355,792</b>

The ongoing expenses were paid out of monies provided by the "Investment Advisor", which are not assets of the Company.

**Guaranteed Investment Products 1 PCC Limited**  
**Notes to the Financial Statements**  
**For the year ended 31 March 2019 (continued)**

**10 RELATED PARTY TRANSACTIONS**

Anson Registrars Limited is the Registrar of the Company. John R Le Prevost is a director of Anson Registrars Limited and during the year £6,181 (31 March 2018: £8,270) of costs were incurred on behalf of the Company, of which £866 (31 March 2018: £615) was owing at the period end in fees to the Registrar.

Santander UK Plc is the immediate parent company of ANTS. The Company is consolidated into the accounts of Santander UK Plc. Notwithstanding this fact, the Board consider that the limited rights attaching to the shares held by Abbey National Nominees Limited means that Santander should not be considered the ultimate parent of the Company.

The directors are entitled to remuneration for their services at rates determined by the annual general meeting of the shareholders. In addition, directors are reimbursed for reasonable travelling, hotel and other incidental expenses in respect of attending meetings of the directors or meetings of the Company. See Note 9 for details on directors' expenses.

**11 SUBSEQUENT EVENTS**

On 4 April 2019 the Company redeemed 18,773,489 Protected Cell 240 shares for £20,650,837.

On 6 June 2019 the Company redeemed 8,274,616 Protected Cell 242 shares for £9,102,078.

There are no other events that have occurred between the period end and signing of these financial statements which require disclosure within the financial statements.

**Guaranteed Investment Products 1 PCC Limited**  
**UNAUDITED SCHEDULE OF INVESTMENTS**  
**as at 31 March 2019**

	As at 31 March 2019		As at 31 March 2018	
	NOMINAL GBP	VALUATION GBP	NOMINAL GBP	VALUATION GBP
Cell 224	-	-	5,355,006	7,243,553
Cell 226	-	-	6,726,006	10,301,334
Cell 228	-	-	4,662,341	7,145,498
Cell 230	-	-	6,766,908	10,306,598
Cell 232	-	-	16,364,423	23,390,743
Cell 234	-	-	3,367,156	3,894,039
Cell 236	-	-	27,373,162	32,691,342
Cell 238	-	-	575,794	663,635
Cell 240	18,032,905	20,630,187	18,032,905	20,519,423
Cell 242	7,915,599	9,072,289	7,915,599	9,015,194
Cell 244	10,643,369	11,967,404	10,643,369	11,919,508
Cell 246	-	-	13,561,785	14,803,572
Cell 247	14,786,683	16,786,420	14,786,683	16,487,367
Cell 248	6,610,055	8,160,773	6,610,055	7,759,566
Cell 249	6,525,664	7,906,102	6,525,664	7,575,272
Cell 250	10,061,065	11,490,024	10,061,065	11,171,902
Cell 251	18,588,765	21,414,885	18,588,765	20,746,316
Cell 252	59,126,630	73,742,909	59,126,630	69,322,158
Cell 253	49,672,401	63,280,692	49,672,401	59,235,626
Cell 254	31,214,081	39,174,281	31,214,081	36,792,636
Cell 255	-	-	29,425,456	33,433,430
Cell 256	33,356,442	39,173,901	33,356,442	36,888,785
Cell 257	-	-	19,302,312	20,921,772
Cell 258	6,300,764	7,211,782	6,300,764	6,857,417
Cell 259	23,986,680	28,109,306	23,986,680	26,522,762
Cell 260	30,753,240	35,376,691	30,753,240	33,754,962
Cell 261	17,745,075	20,475,917	17,745,075	19,651,516
Cell 262	33,701,642	39,897,866	33,701,642	38,202,403
Cell 263	40,458,873	48,507,696	40,458,873	45,601,404
Cell 264	28,836,361	33,422,585	28,836,361	31,618,079
Cell 265	25,958,806	29,819,813	25,958,806	28,471,848
Cell 266	3,345,322	3,612,888	3,345,322	3,475,354
Cell 267	8,270,150	8,795,091	8,270,150	8,496,685
Cell 268	3,957,367	4,148,025	3,957,367	4,026,958
Cell 269	18,315,019	18,765,498	18,315,019	18,305,254
Cell 270	12,187,498	12,448,343	12,187,498	12,135,905
<b>TOTAL</b>	<b>520,350,456</b>	<b>613,391,368</b>	<b>653,830,805</b>	<b>749,349,816</b>

**Guaranteed Investment Products 1 PCC Limited  
Directors, Advisors and Other Information**

**DIRECTORS**

Gavin J Farrell  
John R Le Prevost  
Paul J Meader  
Breton Limited (Alternate Director) - resigned 16 May 2018

**ADMINISTRATOR, SECRETARY AND  
RECEIVING AGENT**

JTC Fund Solutions (Guernsey) Limited  
Ground Floor, Dorey Court  
Admiral Park  
St Peter Port  
Guernsey  
GY1 2HT

**REGISTRAR, TRANSFER AGENT,  
PAYING AGENT AND GUARANTEE  
CLAIMS AGENT**

Anson Registrars Limited  
PO Box 426, Anson House  
Havilland Street  
St Peter Port  
Guernsey  
GY1 3WX

**SPONSOR OF ADMISSION TO  
LISTING**

Mourant Securities Limited  
PO Box 186  
Royal Chambers  
St Julian's Avenue  
St Peter Port  
Guernsey  
GY1 4HP

**INVESTMENT ADVISOR**

Santander UK plc  
2 Triton Square  
Regent's Place  
London  
England  
NW1 3AN

**MARKETING AGENT**

Santander ISA Managers  
287 St Vincent Street  
Glasgow  
Scotland  
G2 5NB

**GUARANTOR**

Santander Guarantee Company  
2 Triton Square  
Regent's Place  
London  
England  
NW1 3AN

**Guaranteed Investment Products 1 PCC Limited  
Directors, Advisors and Other Information**

**AUDITORS**

Ernst & Young LLP  
PO Box 9  
Royal Chambers  
St Julian's Avenue  
St Peter Port  
Guernsey GY1 4AF

**SOLICITORS TO THE COMPANY (as to English Law)**

Allen & Overy LLP  
One Bishops Square  
London  
England  
E1 6AD

**ADVOCATES TO THE COMPANY (as to Guernsey Law)**

Mourant Securities Limited  
PO Box 186  
Royal Chambers  
St Julian's Avenue  
St Peter Port  
Guernsey  
GY1 4HP

**REGISTERED OFFICE**

Ground Floor, Dorey Court  
Admiral Park  
St Peter Port  
Guernsey  
GY1 2HT

**INDEPENDENT VALUATION AGENT**

Future Value Consultants  
151 Sheen Lane  
Auckland House  
London  
England  
SW14 8LR